Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Viale, G

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Oct 2011 - 2201-7 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdq738 doi


Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Aromatase Inhibitors--administration & dosage
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant
Double-Blind Method
Drug Administration Schedule
ErbB Receptors--biosynthesis
Female
Humans
Ki-67 Antigen--biosynthesis
Letrozole
Middle Aged
Nitriles--administration & dosage
Prognosis
Receptors, Estrogen--biosynthesis
Receptors, Progesterone--biosynthesis
Tamoxifen--administration & dosage
Triazoles--administration & dosage